checkAd

     117  0 Kommentare Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB - Seite 4

    Lesen Sie auch


    The Castle Biosciences Stock at the time of publication of the news with a fall of -3,93 % to 20,27USD on Nasdaq stock exchange (22. März 2024, 21:00 Uhr).

    Business Wire (engl.)
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 4 von 4

    Verfasst von Business Wire (engl.)
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Long-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNB - Seite 4 Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data highlighting the performance of its DecisionDx-Melanoma test in predicting risk of sentinel lymph …

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer